Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00091754 |
| Other study ID # |
1269 |
| Secondary ID |
5U01HL075572-04 |
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
September 2004 |
| Est. completion date |
June 2008 |
Study information
| Verified date |
September 2021 |
| Source |
The University of Texas Health Science Center, Houston |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
To identify new cellular, metabolic, and genomic correlates of atherosclerotic plaque and
early pathologic changes in the vascular wall and determine their consequences for coronary
heart disease and stroke.
Description:
BACKGROUND:
This study draws upon the existing ARIC cohort of 15,792 members aged 45-64 years at baseline
in 1987-1989 who have completed four clinic exams three years apart with the last exam in
1998. The longitudinal ARIC cohort study focused on new cardiovascular disease [CVD] risk
factors and subclinical measures of atherosclerosis through B-mode ultrasound of the carotid
arteries. The current study collects new and novel risk factors and performs carotid magnetic
resonance imaging (MRI) examinations on a stratified random sample of 1,200 ARIC participants
with high (>85th percentile) carotid intimal-medial thickness [IMT] by ultrasound and 800
participants with <85th percentile IMT.
DESIGN NARRATIVE:
The study examines an informative subset of the bi-ethnic Atherosclerosis Risk in Communities
(ARIC) cohort to identify cellular, metabolic and genomic correlates of atherosclerotic
plaque characteristics and of early changes in the vascular wall. The longitudinal follow-up
and stored DNA in ARIC will allow testing the ability of the genomic correlates of plaque
characteristics to predict incident coronary heart disease and stroke. One thousand two
hundred individuals with high (>85th percentile) carotid artery wall thickness documented by
B-mode ultrasound and 800 individuals sampled from the remainder of the carotid artery wall
thickness distribution (<85th percentile) will receive a contrast-enhanced carotid MRI
examination. Standardized MRI measures will include carotid artery wall thickness, T2 signal
intensity changes and percent contrast enhancement indicative of endothelial dysfunction, and
for those with plaque, fibrous cap thickness, lipid core volume, and calcification. Novel
cellular, metabolic and genomic measures will be collected and will be related to
MRI-measurable plaque characteristics. In particular, flow cytometry will be used to measure
monocyte and platelet presentation of cytokines, growth factors and adhesion molecules, and
cell-cell aggregation. High throughput genotyping methods will be used to measure 5 to 7
polymorphic sites in each of 150 positional, expressional and biologic candidate genes,
permitting multilocus and haplotype genomic analyses. The depth and breadth of existing risk
factor and lifestyle data, extensive follow-up since 1986-89, and accumulation of clinical
outcomes, including coronary heart disease, stroke and arteriosclerosis, contribute
additional strengths to the laboratory and MRI investigations. Inferences will be made both
cross-sectionally and longitudinally, with a special emphasis on genotype plus environment
interaction. The ARIC cohort is in an ideal age range for the research because of the
frequent and documented occurrence of plaque and the spectrum of clinically relevant stages
from plaque initiation to mature fibrosis, calcification and even erosion and near-rupture.
